کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
9016329 | 1128089 | 2005 | 4 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Switching depot antipsychotic drug responders to oral olanzapine
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
MMSEGAFPANSSCGIDepot antipsychoticsGlobal Assessment of Functioning - ارزیابی جهانی عملکردOlanzapine - الانزاپینMini-mental state exam - امتحان وضعیت مینی روانیAIMS - اهدافAbnormal Involuntary Movement Scale - مقیاس غیر مجاز جنبش غیر مجازpositive and negative syndrome scale - مقیاس مثبت و منفی سندرمClinical Global Impression - چشم انداز جهانی بالینی
موضوعات مرتبط
علوم زیستی و بیوفناوری
علم عصب شناسی
روانپزشکی بیولوژیکی
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: Switching depot antipsychotic drug responders to oral olanzapine Switching depot antipsychotic drug responders to oral olanzapine](/preview/png/9016329.png)
چکیده انگلیسی
In an open-label study, 13 patients taking depot antipsychotic medication for greater than 3 years were switched to oral olanzapine. The first 3-month experience has been previously reported. We now describe a second 3-month experience and integrate our observations into a cumulative 6-month report. Monthly, we assessed patients using clinical ratings [Positive and Negative Syndrome Scale (PANSS), Global Assessment of Functioning (GAF), Mini-Mental State Exam (MMSE), and Clinical Global Improvement Scale (CGI)] and side effect parameters [Abnormal Involuntary Movement Scale (AIMS), Association for Methodology and Documentation in Psychiatry psychotropic side effect rating scale (AMDP-5), and weights]. Olanzapine patients showed statistically significant improvement (baseline to endpoint sixth month) in GAF (p=0.015), MMSE (p=0.022), CGI improvement, and AIMS (p=0.038). There was no statistically significant change in PANSS, CGI severity, or AMDP-5 overall side effects. Weight gain over 6 months averaged 8.9 lb. All patients completed the study. Compliance was estimated at 90%, and 81% of patients chose to continue on the oral olanzapine. One patient was hospitalized at the conclusion of the study. Our findings suggest that clinicians may consider oral olanzapine as a viable alternative to depot antipsychotic medications, balancing clinical improvement in some clinical measures with lack of improvement in other clinical measures; and balancing improvement in abnormal involuntary movements with weight gain and its sequelae.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Progress in Neuro-Psychopharmacology and Biological Psychiatry - Volume 29, Issue 1, January 2005, Pages 141-144
Journal: Progress in Neuro-Psychopharmacology and Biological Psychiatry - Volume 29, Issue 1, January 2005, Pages 141-144
نویسندگان
Linda S. Godleski, L. Jane Goldsmith, W. Victor R. Vieweg, Nancy Zettwoch, Dejzi Stikovac, Susan Lewis,